AstraZeneca’s Alexion Hit With Damages Exceeding $130 Million

An AstraZeneca Plc subsidiary is liable for more than $130 million in damages Thursday over its lackluster efforts to commercialize a drug it acquired when it bought Syntimmune Inc. for up to $1.2 billion.

Alexion Pharmaceuticals Inc. breached multiple provisions of the 2018 sale agreement that provided for payments of up to $800 million based on post-deal triggers, a Delaware judge ruled. The company owes $130 million to Syntimmune’s former investors for refusing to pay after reaching the first milestone, plus an additional undetermined amount for ending the drug trials before they could hit other targets, the judge found.

Vice ...